Download PDF
Deutsche Zeitschrift für Onkologie 2016; 48(03): 100-104
DOI: 10.1055/s-0042-113490
Forschung
© Karl F. Haug Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG

Interaktionen von Lebensmitteln und Onkologika: Die klinische Relevanz ist entscheidend

Dieter Kronabel
Further Information

Publication History

Publication Date:
05 October 2016 (online)

    Permissions and Reprints

Zusammenfassung

Pflanzliche Sekundärmetabolite aus unserer täglichen Nahrung können die Metabolisierung von gleichzeitig applizierten Onkologika mit geringer therapeutischer Breite u. U. erkennbar beeinflussen. Mit zahlreichen Untersuchungen/Studien, die Interaktionen zwischen Lebensmittel und Arzneimittel betreffen, wird daher versucht, die Einflüsse der Nahrung auf die Pharmakokinetik der applizierten Arzneimittel abschätzen zu können. All diesen Bemühungen ist jedoch gemeinsam, dass sie leider nur unzureichend in ein individual-medizinisches Konzept passen. Die klinische Relevanz einer vermuteten Interaktion Lebensmittel – Onkologika ist insbesondere auch von individuell unterschiedlichen Einflussfaktoren abhängig und könnte daher nur im Einzelfall im Rahmen einer individual-medizinischen Betreuung Bedeutung haben.

Summary

Secondary metabolites from plants in our daily diet are -- under certain circumstances -- supposed to influence the metabolism of concurrently administered cancer drugs with a narrow therapeutic range. Numerous investigations and studies are ongoing about the interaction between food and drugs to assess the influence of food on the pharmacokinetics of the administered drugs. However, all these efforts have in common that they, unfortunately, insufficiently fit into an individual-medical concept. The clinical relevance of a suspected interaction between food and cancer drugs particularly depends on individually different anthropological factors and could therefore only have a meaning in individual cases in the context of individual medical care.

Schlüsselwörter

Onkologika - Sekundärmetabolite - individual-medizinische Behandlung - Lebensmittel - Ernährung

Keywords

cancer drugs - secondary metabolites - individual medical concept - food - nutrition
 

  • Literatur

  • 1 Andrade C. Potentially significant versus clinically significant drug interactions: pomegranate juice as a case in point. J Clin Psychiatry 2014; 75(4): 292-293
    CrossrefPubMedGoogle Scholar
  • 2 Cheung KL, Kong AN. Molecular targets of dietary phenethyl isothiocyanate and sulforaphane for cancer chemoprevention. AAPS J 2010; 12(1): 87-97
    CrossrefPubMedGoogle Scholar
  • 3 DFG – Senatskommission zur Beurteilung der gesundheitlichen Unbedenklichkeit von Lebensmitteln. Toxikologische Beurteilung von Furocumarinen in Lebensmitteln. Protokoll vom September 2004, aktualisiert in der Fassung vom 25. Januar 2010.
    PubMedGoogle Scholar
  • 4 Farkas D, Greenblatt DJ. Influence of fruit juices on drug disposition: discrepancies between in vitro and clinical studies. Expert Opin Drug Metab Toxicol 2008; 4(4): 381-393
    CrossrefPubMedGoogle Scholar
  • 5 Fuchs K. Untersuchungen der Toxizität von Umweltchemikalien in gentechnisch veränderten Zellen [Dissertation]. München: LMU München; 2006
    Google Scholar
  • 6 Gilead Sciences Canada, Inc. Mississauga. ON L5N 2W3, Product Monograph Pr ZYDELIG ™ Idelalisib Tablets 150 mg/100 mg, 25 March 2015.
    PubMedGoogle Scholar
  • 7 Hombrecher A. Molecular Modelling Studien am humanen Cytochrom P450 1A2 [Dissertation]. Düsseldorf: Universität Düsseldorf; 2005
    Google Scholar
  • 8 Hou XL, Takahashi K, Kinoshita N, Qiu F, Tanaka K, Komatsu K, Takahashi K, Azuma J. Possible inhibitory mechanism of Curcuma drugs on CYP3A4 in 1alpha,25 dihydroxyvitamin D3 treated Caco-2 cells. Int J Pharm 2007; 337(1–2): 169-177
    CrossrefPubMedGoogle Scholar
  • 9 Hughes A-N, O’Brien MER, Petty WJ, Hick J-B, Rankin E, Woll PJ, Dunlop D, Nicolson M, Boinpally R, Wolf J, Price A. Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. JCO 2009; 27(8): 1220-1226
    CrossrefPubMedGoogle Scholar
  • 10 Jensen K, Ni Y, Panagiotou G, Kouskoumvekaki I. Developing a molecular roadmap of drug-food interactions. PLoS Comput Biol 2015; 11(2): e1004048 DOI: 10.1371/journal.pcbi.1004048.
    CrossrefPubMedGoogle Scholar
  • 11 Jian Y, Bingfang Y. Photochemotherapeutic Agent 8-Methoxypsoralen Induces Cytochrome P450 3A4 and Carboxylesterase HCE2: Evidence on an Involvement of the Pregnane X Receptor. Toxicol Sci 2007; 95(1): 13-22
    CrossrefPubMedGoogle Scholar
  • 12 Kang AY, Young LR, Dingfelder C, Peterson S. Effects of furanocoumarins from apiaceous vegetables on the catalytic activity of recombinant human cytochrome P-4501A2. Protein J 2011; 30(7): 447-456
    CrossrefPubMedGoogle Scholar
  • 13 Klaassen T. Entwicklung und Validierung von Phänotypisierungsmethoden für die Cytochrom P450-Enzyme CYP1A2,CYP2B6, CYP2C9 und CYP2C19 des Menschen [Dissertation]. Bonn: Universität Bonn; 2006
    Google Scholar
  • 14 Kronabel D. Möglicher Einfluss von Lebensmitteln auf die Metabolisierung von Flutamid. Dtsch Z Onkol 2013; 45(4): 163-166
    PubMedGoogle Scholar
  • 15 Kronabel D. Möglicher Einfluss von Lebensmitteln auf die Metabolisierung einiger Tyrosinkinase-Inhibitoren. Dtsch Z Onkol 2013; 45(3): 112-115
    PubMedGoogle Scholar
  • 16 Kronabel D. Möglicher Einfluss von Lebensmitteln auf die Metabolisierung von Tamoxifen. Dtsch Z Onkol 2013; 45(1): 14-17
    PubMedGoogle Scholar
  • 17 Kronabel D. Können Lebensmittel die Metabolisierung von Idelalisib beeinflussen?. Dtsch Z Onkol 2015; 47(4): 183-185
    PubMedGoogle Scholar
  • 18 Lampe JW, King IB, Li S, Grate MT, Barale KV, Chen C, Feng Z, Potter JD. Brassica vegetables increase and apiaceous vegetables decrease cytochrome P450 1A2 activity in humans: changes in caffeine metabolite ratios in response to controlled vegetable diets. Carcinogenesis. 2000. 21(6). 1157-1162
    Google Scholar
  • 19 Ozono S, Yamaguchi A, Mochizuki H et al. Cafeine test in predicting flutamide-induced hepatic injury in patients with prostate cancer. Prostate Cancer Prostatic Dis 2002; 5(2): 128-131
    CrossrefPubMedGoogle Scholar
  • 20 Noll EM, Eisen C, Stenzinger A, Espinet E, Muckenhuber A, Klein C, Vogel V, Klaus B, Nadler W, Rösli C, Lutz C, Kulke M, Engelhardt J, Zickgraf FM, Espinosa O, Schlesner M et al. CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. Nat Med 2016; 22(3): 278-287
    CrossrefPubMedGoogle Scholar
  • 21 Peterson S, Schwarz Y, Shuying S et al. CYP1A2, GSTM1, and GSTT1 polymorphisms and diet effects on CYP1A2 activity in a crossover feeding trial. Cancer Epidemiol Biomarkers Prev 2009; 18(11): 3118-3125
    CrossrefPubMedGoogle Scholar
  • 22 Peterson S, Lampe JW, Bammler TK, Gross-Steinmeyer K. Apiaceous vegetable constituents inhibit human cytochrome P-450 1A2 (hCYP1A2) activity and hCYP1A2-mediated mutagenicity of aflatoxin B1. Food Chem Toxicol 2006; 44(9): 1474-1484
    CrossrefPubMedGoogle Scholar
  • 23 Piao Y, Shin SC, Choi JS. Effects of oral kaempferol on the pharmacokinetics of tamoxifen and one of its metabolites, 4-hydroxytamoxifen, after oral administration of tamoxifen to rat. Biopharm Drug Dispos 2008; 29(4): 245-249
    CrossrefPubMedGoogle Scholar
  • 24 Sachse C, Bhambra U, Smith G, Lightfoot TJ, Barrett JH, Scollay J, Garner RC, Boobis AR, Wolf CR, Gooderham NJ. Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. Br J Clin Pharmacol 2003; 55(1): 68-76
    CrossrefPubMedGoogle Scholar
  • 25 Shin SC, Choi JS. Effects of epigallocatechin gallate on the oral bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rat. Anticancer Drugs 2009; 20(7): 584-588
    CrossrefPubMedGoogle Scholar
  • 26 Subehan Zaidi SF, Kadota S, Tezuka Y. Inhibition on human liver cytochrome P450 3A4 by constituents of fennel (Foeniculum vulgare): identification and characterization of a mechanism-based inactivator. J Agric Food Chem 2007; 55(25): 10162-10167
    CrossrefPubMedGoogle Scholar
  • 27 Tang NY, Huang YT, Yu CS, Ko YC, Wu SH, Ji BC, Yang JS, Yang JL, Hsia TC, Chen YY, Chung JG. Phenethyl isothiocyanate (PEITC) promotes G2/M phase arrest via p53 expression and induces apoptosis through caspase- and mitochondria-dependent signaling pathways in human prostate cancer DU 145 cells. Anticancer Res 2011; 31(5): 1691-1702
    PubMedGoogle Scholar
  • 28 Tomohiro Suzumura, Tatsuo Kimura Shinzoh Kudoh, Kanako Umekawa, Misato Nagata, Kuniomi Matsuura, Hidenori Tanaka, Shigeki Mitsuoka, Naruo Yoshimura, Yukimi Kira, Toshiyuki Nakai, Kazuto Hirata Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer. BMC Cancer 2012; (12): 568
    PubMedGoogle Scholar
  • 29 van Erp NP, Baker SD, Zandvliet AS, Ploeger BA, den Hollander M, Chen Z, den J, König-Quartel JM, Guchelaar HJ, Gelderblom H. Marginal increase of sunitinib exposure by grapefruit juice. Cancer Chemother Pharmacol 2011; 3: 695-703
    PubMedGoogle Scholar
  • 30 Vukovic V, Ianuale C, Leoncini E, Pastorino R, Gualano MR, Amore R, Boccia S. Lack of association between polymorphisms in the CYP1A2 gene and risk of cancer: evidence from meta-analyses. BMC Cancer 2016; 16: 83
    CrossrefPubMedGoogle Scholar